Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891602 | 0.89 | POLB (0.34) | ABL1RIN1POLB | |
| SCHEMBL891439 | 0.88 | POLB (0.35) | ABL1RIN1POLBMAPTKMT2A | |
| SCHEMBL891166 | 0.88 | LMNA (0.40) | POLBALDH1A1MAPT | |
| SCHEMBL891674 | 0.87 | POLB (0.33) | ABL1RIN1POLB | |
| SCHEMBL891685 | 0.85 | POLB (0.34) | ABL1RIN1POLB | |
| SCHEMBL891474 | 0.85 | POLB (0.33) | ABL1RIN1POLBMEN1KMT2A | |
| SCHEMBL891726 | 0.84 | ABL1 (0.43) | ABL1RIN1POLB | |
| SCHEMBL891417 | 0.83 | POLB (0.34) | ABL1RIN1POLBMAPT | |
| SCHEMBL891703 | 0.82 | POLB (0.33) | ABL1RIN1POLB | |
| SCHEMBL891605 | 0.82 | POLB (0.39) | ABL1RIN1POLBMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | XENOPORT, INC. (US) | 2012-04-05 | — | — | US | claimed |
| US-8058260-B2 | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-15 | — | — | US | claimed |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | claimed |
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | XENOPORT, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8058260-B2 | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082645-A1 | 2'-C-METHYL-RIBOFURANOSYL CYTIDINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MTAP, NSUN2, CDA | BCHE 700/4885ABL1 2670/4885RIN1 2712/4885 |
| US-20070270374-A1 | 2'-C-Methyl-Ribofuranosyl Cytidine Prodrugs, Pharmaceutical Compositions and Uses Thereof | MTAP, NSUN2, PAICS | BCHE 793/4885ABL1 2560/4885RIN1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.